URGN UroGen Pharma Ltd
- 13.300
- -0.250-1.85%
- 13.490
- +0.190+1.43%
UroGen Pharma Ltd News
UroGen Pharma Is Maintained at Outperform by Oppenheimer
UroGen Pharma Is Maintained at Outperform by Oppenheimer
Oppenheimer: UroGen Pharma (URGN.US) rating was maintained, and the target price was adjusted from superior to superior to market, and the target price was adjusted from $34.00 to $32.00.
Oppenheimer: UroGen Pharma (URGN.US) rating was maintained, and the target price was adjusted from superior to superior to market, and the target price was adjusted from $34.00 to $32.00.
Oppenheimer Maintains Outperform on UroGen Pharma, Lowers Price Target to $32
Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and lowers the price target from $34 to $32.
Earnings Call Summary | UroGen Pharma Ltd(URGN.US) Q1 2024 Earnings Conference
The following is a summary of the UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript:Financial Performance:UroGen Pharma reported Q1 2024 revenue of $18.8 million, showing a 10% increase than
UroGen Pharma Ltd (URGN) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...
UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript
UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript
UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations
UroGen Pharma (URGN.US): The 2024 Q1 financial report achieved revenue of US$18.781 million, with a previous value of US$17.192 million, with an expected value of US$21.38 million; earnings per share of -0.97 USD, previous value of -1.30 USD, and expected
UroGen Pharma (URGN.US): The 2024 Q1 financial report achieved revenue of US$18.781 million, with a previous value of US$17.192 million, with an expected value of US$21.38 million; earnings per share of -0.97 USD, previous value of -1.30 USD, and expected value of -0.87 USD.
UroGen Pharma Ltd | 10-Q: Quarterly report
Earnings Flash (URGN) UROGEN PHARMA Posts Q1 Revenue $18.8M, Vs. Street Est of $21.4M
08:04 AM EDT, 05/13/2024 (MT Newswires) -- Earnings Flash (URGN) UROGEN PHARMA Posts Q1 Revenue $18.8M, vs. Street Est of $21.4M
UroGen Pharma Q1 EPS $(0.97) Misses $(0.87) Estimate, Sales $18.78M Miss $21.38M Estimate
UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.87) by 11.49 percent. This is a 25.38 percent increase over losses of $(1.
Press Release: UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights -- 12-month duration of response da
UroGen Pharma 1Q Loss $32.3M >URGN
UroGen Pharma 1Q Loss $32.3M >URGN
UroGen Pharma Ltd.'s (NASDAQ:URGN) Path To Profitability
With the business potentially at an important milestone, we thought we'd take a closer look at UroGen Pharma Ltd.'s (NASDAQ:URGN) future prospects. UroGen Pharma Ltd., a biotechnology company, engage
Earnings Preview: URGN to Report Financial Results Pre-market on May 13
$UroGen Pharma Ltd(URGN.US)$ is scheduled to release its financial results pre-market on May 13. Earnings PreviewAnalysts estimate $UroGen Pharma Ltd(URGN.US)$ to post revenue of USD21.39 million for
Reported Saturday, UroGen Announced ATLAS Study Results At AUA 2024: UGN-102 Demonstrates Sustained Response In New And Recurrent Bladder Cancer Patients
New and Recurrent Patients Treated with UGN-102 Achieved Similar Durability of Response Rates (DOR) at 12 monthsUroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commerci
Reported Sunday, JELMYTO Demonstrates Remarkable 86% Recurrence-Free Survival Rate At 24 Months For All Studied Patient And Disease Characteristics
There Were No Differences in RFS Regarding Usage for Chemoablation or Post-Endoscopic Ablation, Tumor Size, Multifocality, or Tumor LocationRFS Was 100% in Patients who Received Maintenance therapy vs
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months With JELMYTO Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
There Were No Differences in RFS Regarding Usage for Chemoablation or Post-Endoscopic Ablation, Tumor Size, Multifocality, or Tumor Location RFS Was 100% in Patients who Received Maintenance therapy vs 61% for
UroGen Announces Results From ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier methods the probabilities of remaining in complete response for both new and recurrent low-grade intermediate-risk non- muscle invasive bladder cancer (LG-IR-NMIBC) patients following treatment with investigational drug UGN-102 as primary therapy, with or without subsequent transurethral resection of the bladder tumor (TURBT) at 3 months.
New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
60% Complete Response Rate after JELMYTO Induction 25% of Patients Received a Ureteral Stent UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that
Analysis
Price Target
No Data
